Seroquel Half-Life
The elimination half-life of quetiapine (Seroquel) is approximately 6 hours in adults at therapeutic doses 1.
Key Pharmacokinetic Details
According to the FDA label, quetiapine demonstrates the following elimination characteristics 1:
- Mean terminal half-life: ~6 hours within the proposed clinical dose range in adults
- Steady-state achievement: 2 days of dosing
- Time to peak concentration (Tmax): 1.5 hours after oral administration
- Primary elimination route: Hepatic metabolism via CYP3A4
Age-Related Variations
Pediatric Patients (10-17 years)
The mean quetiapine half-life is approximately 6 hours, similar to adults 2. Pharmacokinetic profiles in children aged 10 years and older are comparable to adults, suggesting no dosage adjustment is required based on age alone 2.
Elderly Patients (≥65 years)
Oral clearance is reduced by 40% compared to younger patients, which may effectively prolong the half-life 1. Dosing adjustment is necessary in this population.
Clinical Context: Half-Life in Overdose
Important caveat: In acute quetiapine intoxication, the typical half-life extends to approximately 16.5 hours—significantly longer than therapeutic doses 3. This prolonged elimination in overdose situations is critical for managing toxicity and monitoring duration.
Special Populations
- Renal impairment: 25% lower mean oral clearance in severe renal impairment, but this has minimal impact on half-life 1
- Hepatic impairment: May reduce clearance and effectively prolong half-life 1
- No effect from: Gender, race, or smoking status 1
Receptor Occupancy vs. Plasma Half-Life
Research demonstrates a disconnect between plasma half-life and clinical effect 4. While plasma half-life is ~6 hours, dopamine D2 receptor occupancy half-life is approximately 10 hours, and serotonin 5HT2 receptor blockade persists even longer with a half-life of 27 hours 4. This pharmacodynamic profile supports twice-daily dosing despite the relatively short plasma half-life.